<div id="readability-page-1"><p>Acorn Capital Advisors LLC grew its holdings in  Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Free Report) by 13.1% during the first quarter, according to the company in its most recent filing with the SEC. The fund owned 3,235,387 shares of the company's stock after acquiring an additional 373,562 shares during the quarter. Y-mAbs Therapeutics comprises  9.3% of Acorn Capital Advisors LLC's investment portfolio, making the stock its 3rd biggest holding. Acorn Capital Advisors LLC owned about 7.14% of Y-mAbs Therapeutics worth $14,333,000 as of its most recent SEC filing.</p><ul><li>How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?</li></ul><p>A number of other hedge funds have also made changes to their positions in YMAB. Infinitum Asset Management LLC purchased a new position in shares of  Y-mAbs Therapeutics in the 4th quarter valued at about $1,218,000.  Paradigm Biocapital Advisors LP increased its holdings in shares of  Y-mAbs Therapeutics by 3.7% in the 4th quarter. Paradigm Biocapital Advisors LP now owns 4,236,346 shares of the company's stock valued at $33,171,000 after acquiring an additional 150,000 shares during the last quarter.  AQR Capital Management LLC increased its holdings in shares of  Y-mAbs Therapeutics by 869.3% in the 1st quarter. AQR Capital Management LLC now owns 164,788 shares of the company's stock valued at $730,000 after acquiring an additional 147,788 shares during the last quarter.  Stonepine Capital Management LLC purchased a new position in shares of  Y-mAbs Therapeutics in the 1st quarter valued at about $581,000.  Finally, Nuveen LLC purchased a new position in shares of  Y-mAbs Therapeutics in the 1st quarter valued at about $498,000. Hedge funds and other institutional investors own  70.85% of the company's stock. </p><div><p><span></span><span>Get <strong>Y-mAbs Therapeutics</strong> alerts:</span></p></div><h2>Y-mAbs Therapeutics Stock Up 0.1%</h2><p>NASDAQ:YMAB opened at $8.55 on Friday. The stock's 50 day moving average price is $6.05 and its 200 day moving average price is $5.20. The company has a market capitalization of $388.51 million, a PE ratio of -17.10 and a beta of 0.57. Y-mAbs Therapeutics, Inc. has a 52-week low of $3.55 and a 52-week high of $16.11. </p><p>Y-mAbs Therapeutics (NASDAQ:YMAB - Get Free Report) last posted its quarterly earnings data on Friday, August 8th. The company reported ($0.07) earnings per share for the quarter, topping analysts' consensus estimates of ($0.27) by $0.20. Y-mAbs Therapeutics had a negative return on equity of 24.60% and a negative net margin of 26.03%.The company had revenue of $19.52 million during the quarter, compared to analysts' expectations of $18.40 million.  As a group, sell-side analysts anticipate that  Y-mAbs Therapeutics, Inc. will post -0.65 EPS for the current fiscal year. </p><h2>Wall Street Analyst Weigh In</h2><p>A number of research firms have recently commented on YMAB. Oppenheimer downgraded Y-mAbs Therapeutics from an &#34;outperform&#34; rating to a &#34;market perform&#34; rating in a report on Tuesday, August 5th. HC Wainwright  reiterated a &#34;neutral&#34; rating and issued a $8.60 price objective (down previously from $11.00) on shares of Y-mAbs Therapeutics in a report on Wednesday, August 6th. Morgan Stanley  set a $8.60 price target on Y-mAbs Therapeutics in a research note on Tuesday, August 5th. Jones Trading downgraded Y-mAbs Therapeutics from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a research note on Tuesday, August 5th. Finally, Cantor Fitzgerald  set a $8.60 price target on Y-mAbs Therapeutics and gave the stock a &#34;neutral&#34; rating in a research note on Tuesday, August 5th. Eight equities research analysts have rated the stock with a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of &#34;Reduce&#34; and an average price target of $9.62.</p><p><b>Get Our Latest Stock Analysis on Y-mAbs Therapeutics</b></p><h2>About Y-mAbs Therapeutics</h2> (Free Report)<p>Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.</p><h2>Further Reading</h2><ul><li>Five stocks we like better than Y-mAbs Therapeutics</li><li>How to Profit From Growth Investing </li><li>MarketBeat Week in Review – 08/25 - 08/29</li><li>Special Purpose Acquisition Company (SPAC) What You Need to Know </li><li>Improving Fundamentals Drive New Buybacks for 3 Strong Performers</li><li>What Are the U.K. Market Holidays? How to Invest and Trade</li><li>3 Reasons Gartner Could Be the Best Buy of Q3</li></ul><p><strong>Want to see what other hedge funds are holding YMAB?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9WU1BQg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9WU1BQg"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Y-mAbs Therapeutics Right Now?</h2><p>Before you consider Y-mAbs Therapeutics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Y-mAbs Therapeutics wasn't on the list.</p><p>While Y-mAbs Therapeutics currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

YMAB

<p>Acorn Capital Advisors LLC increased its stake in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) by 13.1% in Q1, now holding 3,235,387 shares, making it the third largest holding in their portfolio. Other hedge funds also adjusted their positions, with institutional investors owning 70.85% of the stock. Y-mAbs Therapeutics reported a revenue of $19.52 million for the last quarter, exceeding expectations. Analysts have mixed ratings on the stock, with an average price target of $9.62 and a consensus rating of "Reduce."</p>

Y-mAbs Therapeutics, Inc. $YMAB Stake Lifted by Acorn Capital Advisors LLC